Most people reading this piece will have heard of Ozempic, Wegovy, Mounjaro and Zepbound. Some may even have tried them (your author has not). However, a recent day spent with Novo – manufacturer of the first two listed drugs – served as a reminder of the enormity of the problem. Newly slim celebrities may be one thing, but only 2% of people living with obesity globally currently receive treatment with GLP-1 medications.
Our focus on this critical future trend dates to 2012. Back then, Novo (and its peer Lilly, the manufacturer of the other two drugs listed above) saw diabetes as a healthcare challenge, treated via insulin. There were limited ways of treating obesity, other than through lifestyle changes. Along came the modern generation of GLP-1 therapies in the early 2020s, and the market was revolutionised. Their appeal lies in effectively mimicking the body’s natural gut hormones to regulate appetite, slow digestion and stabilise blood sugar.
942m adults live with obesity (per Novo’s materials shared with us last week), a figure which is set to grow to over 1.2bn by 2035, equivalent to a 31% increase. Obesity, Novo reminded us, is associated with more than 200 other different healthcare complications. 58% of adults with diabetes have obesity, and life expectancy for a person with Type-2 diabetes is typically reduced by five years. Cardiovascular disease (CVD) remains the leading cause of mortality globally. People living with diabetes and obesity have a 2-3 times higher risk of CVD and heart failure than those without.
Depressing statistics, but there is hope. Much of Novo’s and Lilly’s current focus is increasing GLP-1 adoption. Just 8m patients globally are treated with these drugs today, with the majority residing in the US. Multiple solutions to grow access exist. Consider that over 50% of consumers polled by Novo say that they are reluctant to initiate treatment owing to cost. 30% say they want to see early results of weight loss to stay motivated on their journey, but 33% stop treatment owing to side effects. Against this background, expect more product innovation from a wider range of healthcare businesses. The runway for growth remains enormous
—
Originally Posted September 29, 2026 – Just scratching the surface
The above is provided for information purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Any forward looking statements are based on assumptions that may change. The views expressed are solely those of the author at the time of writing. The author of this piece has no personal direct investment in the business. This article should not be relied upon for investment decisions. Past performance does not predict future returns, the value of investments and income from them can fall as well as rise.
Disclosure: Heptagon Capital
The document is provided for information purposes only and does not constitute investment advice or any recommendation to buy, or sell or otherwise transact in any investments. The document is not intended to be construed as investment research. The contents of this document are based upon sources of information which Heptagon Capital believes to be reliable. However, except to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to the accuracy or completeness of this document or its contents and, Heptagon Capital, its affiliate companies and its members, officers, employees, agents and advisors do not accept any liability or responsibility in respect of the information or any views expressed herein. Opinions expressed whether in general or in both on the performance of individual investments and in a wider economic context represent the views of the contributor at the time of preparation. Where this document provides forward-looking statements which are based on relevant reports, current opinions, expectations and projections, actual results could differ materially from those anticipated in such statements. All opinions and estimates included in the document are subject to change without notice and Heptagon Capital is under no obligation to update or revise information contained in the document. Furthermore, Heptagon Capital disclaims any liability for any loss, damage, costs or expenses (including direct, indirect, special and consequential) howsoever arising which any person may suffer or incur as a result of viewing or utilising any information included in this document.
The document is protected by copyright. The use of any trademarks and logos displayed in the document without Heptagon Capital’s prior written consent is strictly prohibited. Information in the document must not be published or redistributed without Heptagon Capital’s prior written consent.
Heptagon Capital LLP, 63 Brook Street, Mayfair, London W1K 4HS
tel +44 20 7070 1800
fax +44 20 7070 1881
email london@heptagon-capital.com
Partnership No: OC307355 Registered in England and Wales Authorised & Regulated by the Financial Conduct Authority
Disclosure: Interactive Brokers Third Party
Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from Heptagon Capital and is being posted with its permission. The views expressed in this material are solely those of the author and/or Heptagon Capital and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
Join The Conversation
If you have a general question, it may already be covered in our FAQs page. go to: IBKR Ireland FAQs or IBKR U.K. FAQs. If you have an account-specific question or concern, please reach out to Client Services: IBKR Ireland or IBKR U.K..
Visit IBKR U.K. Open an IBKR U.K. Account